Diabetes Antibody Standardization Program:: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2

被引:219
作者
Torn, C. [2 ]
Mueller, P. W. [3 ]
Schlosser, M. [4 ,5 ]
Bonifacio, E. [6 ]
Bingley, P. J. [1 ]
机构
[1] Univ Bristol, Med Sch Unit, Southmead Hosp, Bristol BS10 5NB, Avon, England
[2] Univ Hosp MAS, Clin Res Ctr, Inst Clin Sci, Unit Diabet & Coeliac Dis, Malmo, Sweden
[3] Ctr Dis Control & Prevent, Atlanta, GA USA
[4] Ernst Moritz Arndt Univ Greifswald, Dept Med Biochem & Mol Biol, Karlsburg, Germany
[5] Ernst Moritz Arndt Univ Greifswald, Inst Pathophysiol, Karlsburg, Germany
[6] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, D-8027 Dresden, Germany
关键词
adjusted sensitivity; AUC; GAD autoantibodies; IA-2; autoantibodies; islet autoantibodies; prediction; sensitivity; specificity;
D O I
10.1007/s00125-008-0967-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Islet autoantibodies are important in diabetes classification and risk assessment, and as endpoints in observational studies. The Diabetes Autoantibody Standardization Program (DASP) aims to improve and standardise measurement of autoantibodies associated with type 1 diabetes. We report results for glutamic acid decarboxylase autoantibodies (GADA) and islet antigen-2 autoantibodies (IA-2A) from three DASP workshops (2002-2005). Methods Up to 60 laboratories in 18 countries participated in each workshop. Participants received coded serum aliquots from 50 patients with newly diagnosed type 1 diabetes (median age 18 years, range 9-35 years) and 100 blood donor controls. Results were analysed using receiver operator characteristic (ROC) curves with sensitivity adjusted to 95% specificity in workshop controls. Results GADA assays performed well in all three workshops (median area under the ROC curve [AUC] 0.94; interquartile range 0.91-0.95) and performance was similar to DASP 2000. Performance of IA-2A assays improved over the workshop programme. Median AUC was 0.81 (interquartile range 0.79-0.83) in DASP 2002, 0.82 (interquartile range 0.78-0.84) in 2003, and 0.85 (interquartile range 0.82-0.87) in 2005 (p<0.0001). Performance of GADA ELISA improved between 2002 and 2005, and, in DASP 2005, achieved higher median AUC and adjusted sensitivity than RIA. IA-2A ELISA improved and, in DASP 2005, achieved AUCs equivalent to in-house RIA. Assays using IA-2ic or full length IA-2 clones were more sensitive than those using IA-2bdc, with higher AUC (p=0.004). Conclusions/Interpretation GADA and IA-2A assays perform well in discriminating health and disease. The workshop format highlights systematic differences related to assay method and allows full evaluation of novel methods. The programme of autoantibody workshops in type 1 diabetes provides a model for other autoimmune diseases.
引用
收藏
页码:846 / 852
页数:7
相关论文
共 18 条
[1]   Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program [J].
Achenbach, Peter ;
Schlosser, Michael ;
Williams, Alistair J. K. ;
Yu, Liping ;
Mueller, Patricia W. ;
Bingley, Polly J. ;
Bonifacio, Ezio .
CLINICAL IMMUNOLOGY, 2007, 122 (01) :85-90
[2]   Diabetes antibody standardization program: First assay proficiency evaluation [J].
Bingley, PJ ;
Bonifacio, E ;
Mueller, PW .
DIABETES, 2003, 52 (05) :1128-1136
[3]  
Bonifacio E, 1988, Autoimmunity, V1, P59, DOI 10.3109/08916938808997177
[4]   ASSESSMENT OF PRECISION, CONCORDANCE, SPECIFICITY, AND SENSITIVITY OF ISLET CELL ANTIBODY MEASUREMENT IN 41 ASSAYS [J].
BONIFACIO, E ;
BOITARD, C ;
GLEICHMANN, H ;
SHATTOCK, MA ;
MOLENAAR, JL ;
BOTTAZZO, GF .
DIABETOLOGIA, 1990, 33 (12) :731-736
[5]   ISLET AUTOANTIBODY MARKERS IN IDDM - RISK ASSESSMENT STRATEGIES YIELDING HIGH-SENSITIVITY [J].
BONIFACIO, E ;
GENOVESE, S ;
BRAGHI, S ;
BAZZIGALUPPI, E ;
LAMPASONA, V ;
BINGLEY, PJ ;
ROGGE, L ;
PASTORE, MR ;
BOGNETTI, E ;
BOTTAZZO, GF ;
GALE, EAM ;
BOSI, E .
DIABETOLOGIA, 1995, 38 (07) :816-822
[6]   IMMUNOLOGY AND DIABETES WORKSHOPS - REPORT OF THE 1ST INTERNATIONAL WORKSHOP ON THE STANDARDIZATION OF CYTOPLASMIC ISLET CELL ANTIBODIES - SUMMARY OF A WORKSHOP ORGANIZED BY THE JUVENILE-DIABETES-FOUNDATION-INTERNATIONAL HELD IN MONTE-CARLO ON 31 OCTOBER AND 1 NOVEMBER 1985 [J].
BOTTAZZO, GF ;
GLEICHMANN, H .
DIABETOLOGIA, 1986, 29 (02) :125-126
[7]   AutoAbSC.Org - Autoantibody standardization committee in 2006 [J].
Chan, Edward K. L. ;
Fritzler, Marvin J. ;
Wiik, Allan ;
Andrade, Luis E. C. ;
Reeves, Westley H. ;
Tincani, Angela ;
Meroni, Pier Luigi .
AUTOIMMUNITY REVIEWS, 2007, 6 (08) :577-580
[8]   GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives [J].
Dittler, J ;
Seidel, D ;
Schenker, M ;
Ziegler, AG .
DIABETES, 1998, 47 (04) :592-597
[9]   European Nicotinamide Diabetes Intervention Trial (ENDIT):: a randomised controlled trial of intervention before the onset of type 1 diabetes [J].
Gale, EAM ;
Bingley, PJ ;
Knip, M ;
Emmett, CL ;
Swankie, H ;
Fewell, S ;
Kearsey, P ;
Schober, E ;
Gorus, FK ;
Dupre, J ;
Mahon, JL ;
Profozic, V ;
Reimers, JI ;
Mandrup-Poulsen, T ;
Levy-Marchal, C ;
Jaeger, C ;
Bartsocas, C ;
Vazeou, A ;
Györko, M ;
Soltesz, G ;
Madacsy, L ;
Pastore, MR ;
Pozzilli, P ;
Dahl-Jorgensen, K ;
Joner, G ;
Kinalska, I ;
Mrozikiewicz, A ;
Vaykhonsky, Y ;
de Leiva, A ;
Martinez-Larrad, MT ;
Mauricio, D ;
Serrano-Rios, M ;
Ludvigsson, J ;
Schoenle, EJ ;
Yilmaz, MT ;
Carson, DJ ;
Tennet, H ;
Robertson, K ;
Gillespie, KM ;
Gillmor, H ;
Moore, WPT ;
Norcross, A ;
Williams, AJK ;
Dinesen, B ;
Kjellberg, S ;
Akelsen, HE ;
Thorsby, E ;
Undlien, DE ;
Collier, T ;
Hardy, P .
LANCET, 2004, 363 (9413) :925-931
[10]  
Gavin JR, 1997, DIABETES CARE, V20, P1183